Cantor Fitzgerald Analysts Lower Earnings Estimates for UTHR

Key Points

• Cantor Fitzgerald analysts have decreased their FY2025 earnings per share (EPS) estimate for United Therapeutics from $28.53 to $28.43, while maintaining an "Overweight" rating with a target price of $405.00.
• United Therapeutics reported quarterly earnings of $6.41 per share, missing consensus estimates of $6.80, despite a year-over-year revenue increase of 11.7%.
• Institutional investors hold 94.08% of United Therapeutics' stock, indicating strong investment interest, while recent insider transactions show notable selling activity by company executives.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of United Therapeutics in a report released on Thursday, July 31st. Cantor Fitzgerald analyst O. Brayer now anticipates that the biotechnology company will post earnings of $28.43 per share for the year, down from their previous estimate of $28.53. Cantor Fitzgerald currently has a "Overweight" rating and a $405.00 target price on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the firm earned $5.85 EPS. The company's revenue was up 11.7% on a year-over-year basis.

UTHR has been the subject of several other research reports. HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the stock a "buy" rating in a research note on Thursday. Wells Fargo & Company reduced their price target on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a report on Thursday. Bank of America dropped their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Finally, Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $379.69.

United Therapeutics Trading Down 2.6%

UTHR stock opened at $274.70 on Friday. The stock has a market cap of $12.39 billion, a PE ratio of 10.72, a P/E/G ratio of 6.15 and a beta of 0.53. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $417.82. The company has a 50-day moving average price of $298.39 and a 200 day moving average price of $314.07.

Insider Buying and Selling at United Therapeutics

In other news, Director Nilda Mesa sold 645 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the sale, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. The trade was a 11.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at $10,297,208.76. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 70,681 shares of company stock valued at $21,318,359 in the last 90 days. Insiders own 10.30% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock valued at $1,374,001,000 after buying an additional 15,312 shares during the last quarter. FMR LLC lifted its position in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after acquiring an additional 393,777 shares during the last quarter. Geode Capital Management LLC lifted its position in United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after acquiring an additional 44,277 shares during the last quarter. AQR Capital Management LLC boosted its stake in United Therapeutics by 0.8% in the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock valued at $344,176,000 after acquiring an additional 7,710 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in United Therapeutics by 0.7% in the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company's stock worth $192,571,000 after purchasing an additional 4,145 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.